Evidence map›Paper›PMID 36155145›Full record

ArticleJournal francais d'ophtalmologie2022

[Herpes Zoster Ophthalmicus after Pfizer BNT162b2 and Moderna mRNA-1273 vaccination in two young and immunocompetent patients].

M A Amblard, E Costantini, G Hayek, X Ricaud

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal francais d'ophtalmologie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

M A AmblardCentre ophtalmologique Place de l'Étoile, Luxembourg.
E CostantiniCentre ophtalmologique Place de l'Étoile, Luxembourg; Centre laser Monterey, Luxembourg.
G HayekCentre ophtalmologique Place de l'Étoile, Luxembourg.
X RicaudCentre ophtalmologique Place de l'Étoile, Luxembourg; Centre laser Monterey, Luxembourg. Electronic address: docteur.ricaud@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 19 (COVID-19) was first observed in Wuhan, China. The disease is caused by a virus (SARS-CoV-2), which spread around the world within a matter of weeks, leading to a large number of deaths. While the health crisis was managed on the ground, the scientific community focused on finding a means to stop it. Vaccine candidates such as the mRNA vaccines (Pfizer BTN162b2 and Moderna mRNA-1273), started to emerge. As these treatments came on the market recently, there is still concern about potential side effects, among them, Herpes Zoster Ophthalmicus (HZO).

Indexed as

COVID-19Herpes Zoster Ophthalmicus2019-nCoV Vaccine mRNA-1273BNT162 VaccineHumansSARS-CoV-2Vaccination2019-nCoV Vaccine mRNA-1273BNT162 VaccineCoronavirusCOVID-19Effets secondairesHerpes zoster ophthalmicusModernaPfizerSide effectsVaccinationZona ophtalmique

Identifiers

PMID36155145
PMCPMC9499740

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.